IDWeek 2020: Phase I clinical data for Streptococcus pneumoniae vaccine ASP3772 will be released soon.

Clinical biotech company Affinivax announced today that preliminary data from its Phase I/II clinical trial of ASP3772, the leading vaccine candidate for Streptococcus pneumoniae, will be presented at an international conference.
ASP3772 was developed using Affinivax's proprietary MAPS™ (Multiple Antigen Delivery System) technology, including 24 pneumococcal serotypes and 2 new conservative pneumococcal proteins, which are currently on the market or in clinical trials of any other pneumococcal vaccine.
ASP3772 is being evaluated in Phase I/II clinical studies and has now completed Phase I studies in adults aged 18 to 64 and recently in adults over 65 years of age.
results will be announced at a joint annual meeting of the American Society of Infectious Diseases (IDSA), the American Society for Health Epidemiology (SHEA), the HIV Medical Association (HIVMA) and the Society for Pediatric Infectious Diseases (PIDS).
results show that ASP3772 is safe and well-to-bear among adults aged 18 to 64.
these safety, tolerance and immunogenic data support the continued development of ASP3772, which can be used to protect the elderly, children and infants from Streptococcus pneumoniae.
the study has completed Phase II clinical trials for adults over 65 years of age, and asP3772's clinical development program includes a Phase I study of healthy young children aged 12 to 15 months.
.